YKYi Kang

Yi Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yi Kang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The 14‐day repeated‐dose toxicity studies of a fixed‐dose combination, QXOH/levobupivacaine, via subcutaneous injection in mice

    by Peiwen Gao, Yujun Zhang, Chaoyi Deng, Deying Gong, Yi Kang, Jin Liu, Wensheng Zhang

    QXOH‐LB, a fixed‐dose combination (35 mM QXOH and 10 mM levobupivacaine) has been shown to induce a long duration of local anesthesia in animal efficacy testing, which indicates potential for postoperative pain management. In this study, we evaluated the potential toxicity of QXOH‐LB in NIH mice under the Guidance on the repeated‐dose toxicity published by the China Food and Drug Administration. Mice (n = 30 per sex per group) were subcutaneously injected 5, 10, 20 mg/kg QXOH‐LB, 5, 10, 20 mg/kg QXOH, and 5 mg/kg levobupivacaine (LB) once a day for 14 days with sacrifice of main study animals; remaining mice (n = 10 per sex per group) were monitored for an additional 4‐week recovery period. Mice in the 10 and 20 mg/kg QXOH, and 20 mg/kg QXOH‐LB died, which was considered due to excessive respiratory inhibition. The doses of 10 mg/kg QXOH‐LB and 5 mg/kg QXOH were well tolerated without any clinical signs of toxicity. Therefore, the no‐observed‐adverse‐effect level (NOAEL) of QXOH‐LB and QXOH was considered to be 10 and 5 mg/kg/day, respectively. In the dose range from 5 to 20 mg/kg, the exposure of QXOH and LB in QXOH‐LB was equal to each agent used alone at the same dose in NIH mice. There was no gender difference on exposure and no evidence of accumulation.


  • The 14‐day repeated‐dose toxicity study of a fixed‐dose combination, QXOH/levobupivacaine, via subcutaneous injection in beagle dogs

    by Jie Zhang, YuJun Zhang, Qinqin Yin, Jun Yang, Yi Kang, Deying Gong, Jin Liu, WenSheng Zhang

    QXOH‐Levobupivacaine (LB) is a fixed‐dose combination of 35‐mM QXOH and 10‐mM LB. It was developed for perioperative analgesia because of its long‐acting analgesic effect. The purpose of this study was to evaluate the potential toxicity of QXOH‐LB in beagle dogs in accordance with the Guidance on the repeated‐dose toxicity published by the China Food and Drug Administration. Groups of five male and five female beagle dogs received normal saline, QXOH‐LB (2, 4, and 8 mg/kg, calculated as QXOH), QXOH (2, 4, and 8 mg/kg), or LB (2 mg/kg, equals the concentration of LB in 8‐mg/kg QXOH‐LB group) at the volume of 1 mL/kg once per day for 14 days through subcutaneous injection. No mortality was observed. Dogs in the control group as well as animals treated with 2‐mg/kg QXOH or QXOH‐LB exhibited normal behaviors. Clinical signs of toxicity in dogs treated with 4 and 8 mg/kg of QXOH or QXOH‐LB included decreased activity, unsteady gait, jerks, tremors, vocalization, emesis, ataxia, lateral/sternal recumbency, deep/rapid respiration, and gasping. Additionally, neurological function was found to be affected by QXOH and QXOH‐LB at the doses of 4 and 8 mg/kg. All clinical signs were recovered within 24 h. The no‐observed‐adverse‐effect level of QXOH and QXOH‐LB was considered to be 2 mg/kg. Toxicokinetic data showed that exposure to QXOH and LB increased as QXOH‐LB doses were increased from 4 to 8 mg/kg. There was no evidence of drug accumulation or any effect of gender.


  • Non‐clinical single‐ and repeated‐dose toxicity studies of ET‐26 hydrochloride in rats

    by YiNan Zhang, YuJun Zhang, ChaoYi Deng, DeYing Gong, Yi Kang, Jin Liu, WenSheng Zhang

    ET‐26 hydrochloride (ET‐26HCl), a novel analog of etomidate, induces as effective sedation, with good cardiac and respiratory stability, as etomidate but with mild adrenocortical suppression. The objective of this study was to evaluate the potential adverse effects of ET‐26HCl in rats. In a single‐dose toxicity study, abnormal urine color (red) was observed in all groups: control (100%), 8 mg/kg (10%), 16 mg/kg (50%), and 20 mg/kg (70%) ET‐26HCl, which returned to normal on the day of dosing. There were no mortalities or serious toxicological signs; the maximum tolerable dose of ET‐26HCl was 20 mg/kg. In the repeated‐dose toxicity study, deaths occurred in the 12‐ (13.33% of males) and 16‐mg/kg/day (20% of males and 3.33% of females) groups. Abnormal urine color (red or brown) was detected in the control group (10%) and all treatment groups (30%, 46.67%, and 40% at 8, 12 and 16 mg/kg/day, respectively), at a frequency of 1.43% in the control group, 4.76% in 8 mg/kg/day, 7.62% in 12 mg/kg/day, and 4.29% in 16 mg/kg/day. Increases in neutrophils and plasma fibrinogen were temporary and recoverable effects. Macroscopic and histopathologic changes were found only at the injection sites: abnormal skin color, scabbing, thrombus, ulceration, and inflammation. During the recovery period, there was evidence of reversibility, including fibroblast proliferation and vessel recanalization. The no‐observed‐adverse‐effect level of ET‐26HCl was 8 mg/kg/day. Toxicokinetic variables of ET‐26HCl, except the calculated initial concentration in females on Day 1, showed a dose‐dependent increase to exposure, with no gender difference and no evidence of accumulation.


  • Preclinical safety evaluation of ET‐26 hydrochloride, a novel intravenous anesthetic agent, in beagle dogs

    by YuJun Zhang, ChaoYi Deng, DeYing Gong, Yi Kang, Jin Liu, WenSheng Zhang

    ET‐26 hydrochloride (ET‐26HCl) is a novel etomidate analogue, approved for clinical trials, which has an effective sedative‐hypnotic effect, a stable myocardial performance, and milder adrenocortical suppression than etomidate in rats and beagle dogs. Additionally, ET‐26HCl showed similar hemodynamic stability as etomidate in the rat uncontrolled hemorrhagic shock model. Furthermore, ET‐26HCl, in the rat lipopolysaccharide‐induced sepsis model, was found to have a higher survival rate, a lower inflammatory reaction, and less organ injury. In the present study, we measured the potential adverse effects of ET‐26HCl in beagle dogs in accordance with the Guidance on single‐ and repeated‐dose toxicity published by the China Food and Drug Administration. In toxicity studies, single and repeated (14 days) intravenous doses of up to 16 mg/kg were well tolerated, with only pharmacologically related clinical signs seen in both studies. Thus, the no‐observed‐adverse‐effect level (NOAEL) of ET‐26HCl was found at 16 mg/kg/day. Toxicokinetic examination demonstrated that ET‐26HCl showed a dose‐dependent increase to exposure, no gender difference, and no evidence of accumulation. These results provide useful information for guiding a phase I clinical trial of ET‐26HCl in healthy volunteers.